Clinical trials
Hodgkin Lymphoma clinical trials
Below are recruiting hodgkin lymphoma clinical trials, each written for real people, not researchers. We’re tracking 420 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07256158RecruitingPhase 3
Reducing radiation for early unfavorable Hodgkin lymphoma
This trial tests whether a lower dose of radiation, guided by PET scans, is safe and effective for people with early-stage but unfavorable Hodgkin lymphoma. It aims to reduce side effects while keeping the treatment strong.
AlessandriaAges 18 years+ - NCT06383338RecruitingPhase 1
Metabolism Changes in Young People with Lymphoma
This study looks at how your body's metabolism (processing of food and medicine) changes after you start treatment for lymphoma. It uses two safe, commonly used drugs (omeprazole and dextromethorphan) to measure these changes.
Melbourne, VictoriaAges 6–25 - NCT05826535RecruitingPhase 1/Phase 2
Test of CAR T-cell therapy for aggressive B-cell lymphoma
This Phase 1/2 study tests a lab-made immune cell treatment (CAR T cells) made from your own blood cells to treat aggressive large B-cell lymphoma that has come back or didn’t respond. If you qualify, the goal is to see whether this treatment is safe and can shrink lymphoma.
Irvine, CaliforniaAges 18 years+ - NCT06536049RecruitingPhase 1/Phase 2
Epcoritamab plus ibrutinib for relapsed or refractory aggressive B-cell lymphoma
This trial tests a combination of two drugs – epcoritamab (a type of immunotherapy that helps your immune system attack lymphoma cells) and ibrutinib (a targeted pill that blocks signals that help cancer grow). It is for people with aggressive B-cell lymphoma that has come back or not responded to at least 2 prior treatments.
Minneapolis, MinnesotaAges 18 years+ - NCT07021989RecruitingPhase 2
ctDNA-Guided Therapy for Relapsed Hodgkin Lymphoma
This trial uses a blood test (ctDNA) to guide treatment for Hodgkin lymphoma that has come back or not responded to one prior treatment. You would receive a combination of drugs (pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin) to see if it works better.
Davis, CaliforniaAges 18 years+ - NCT07519772RecruitingPhase 1/Phase 2
Testing MK-1045 for Hard-to-Treat Lymphoma
This study tests a new drug called MK-1045 for people with follicular lymphoma or diffuse large B-cell lymphoma (two types of blood cancer) that hasn't responded to at least two previous treatments. The drug is designed to target cancer cells and may help people whose cancer has come back or stopped responding to therapy.
Denver, ColoradoAges 18 years+ - NCT07451054RecruitingPhase 1
Stem cells plus CAR T-cells for lymphoma
This trial tests a new treatment that combines your own stem cells with special immune cells (CAR T-cells) that target a marker called CD45 on lymphoma cells. It may help people whose lymphoma has not responded to multiple prior therapies.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06209619RecruitingPhase 1
Study of CC-99282 plus rituximab after CAR-T for lymphoma
This trial tests combining an experimental pill (CC-99282) with the immunotherapy drug rituximab for people with B-cell non-Hodgkin's lymphoma whose cancer did not fully respond to CAR-T cell therapy. The goal is to improve results after CAR-T.
Columbus, OhioAges 18 years+ - NCT05873712RecruitingPhase 2
Zanubrutinib plus CAR-T for Richter syndrome
This Phase 2 trial tests whether a combination of zanubrutinib (an oral medicine) and CAR-T cell therapy can treat Richter syndrome, a type of lymphoma that develops in people with CLL/SLL. It may help shrink tumors and improve outcomes after the disease comes back or doesn’t respond to prior treatment.
New York, New YorkAges 18 years+ - NCT06395870RecruitingPhase 1
Dual-target cell therapy for returning B-cell lymphoma
This trial tests a new cell therapy that targets two proteins (CD19 and CD20) found on certain lymphoma cells. It is for patients whose B-cell non-Hodgkin lymphoma has come back or not responded to at least two prior treatments. The goal is to see if this therapy can help control the cancer.
Hefei, AnhuiAges 18–75 - NCT05039073RecruitingPhase 2
Brentuximab plus nivolumab for Hodgkin lymphoma after prior treatment
This Phase 2 study tests brentuximab and nivolumab (two anti-cancer medicines) in people with classical Hodgkin lymphoma that has come back or did not respond to earlier treatment. It may help by attacking lymphoma cells in different ways, especially after limited options from prior therapies.
Atlanta, GeorgiaAges 12 years+ - NCT06745076RecruitingPhase 2
Using a blood test to safely lower chemo for advanced Hodgkin lymphoma
This trial studies whether a blood test (ctDNA) can help doctors safely reduce chemotherapy for people with advanced Hodgkin lymphoma. If you have stage 3 or 4 Hodgkin lymphoma that hasn't been treated yet and are healthy enough for strong chemo, this study may be an option for you.
Irvine, CaliforniaAges 18 years+ - NCT06190067RecruitingPhase 2
Azacitidine plus PD-1 for relapsed Hodgkin lymphoma
This trial tests a combination of two medicines—azacitidine and a PD-1 inhibitor—for people with Hodgkin lymphoma that has returned or not responded to previous treatment. The aim is to see if this combination can help control the disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07093411RecruitingEarly Phase 1
Targeted cell therapy for relapsed B-cell lymphoma
This trial tests a new type of cell therapy that targets two proteins (CD19 and CD20) found on certain lymphoma cells. It is designed for patients whose lymphoma has not responded to or has returned after previous treatment, and who cannot or choose not to receive standard CAR-T therapy.
HefeiAges 18–75 - NCT06386315RecruitingPhase 2
Lower dose radiation for slow-growing lymphoma
This trial tests whether giving a lower dose of radiation than usual works well for people with slow-growing B-cell lymphomas. It aims to reduce side effects while still controlling the disease.
Scottsdale, ArizonaAges 18 years+ - NCT06822855Recruiting
Improving How We Predict Hodgkin Lymphoma Outcomes
This trial is looking at new ways to predict how Hodgkin lymphoma will respond to treatment. It collects blood and tumor samples at key times to see if these can help doctors make better treatment decisions in the future.
Milan, MIAges 18 years+ - NCT07188558RecruitingPhase 3
Comparing ronde-cel to standard CAR T-cell therapy for large B-cell lymphoma
This trial tests a new treatment called ronde-cel against the usual CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded to initial treatment. The goal is to see if ronde-cel works better.
Gilbert, ArizonaAges 18 years+ - NCT07082803RecruitingPhase 1
TLN-121 for relapsed or refractory non-Hodgkin lymphomas
This trial tests a new drug called TLN-121 for people with certain types of non-Hodgkin lymphoma that have come back or not responded to previous treatments. It aims to see if the drug is safe and effective.
Palo Alto, CaliforniaAges 18 years+ - NCT03618550RecruitingPhase 2
Pembrolizumab plus chemotherapy for relapsed Hodgkin lymphoma
This study tests a combination of the immunotherapy drug pembrolizumab with a chemotherapy regimen called GVD for patients whose Hodgkin's lymphoma has not responded or has returned after initial treatment. The goal is to see if this combination works better than standard approaches.
Duarte, CaliforniaAges 18 years+ - NCT03017820RecruitingPhase 1
Vaccine plus immune drugs for relapsed blood cancers
This early-phase trial tests a personalized-style vaccine (called VSV-hIFNβ-NIS) given alone or with other cancer-fighting medicines, including drugs that help the immune system attack. It is designed for people with certain relapsed or hard-to-treat multiple myeloma, acute myeloid leukemia, or lymphomas, to see if the treatment can shrink tumors and improve outcomes.
Scottsdale, ArizonaAges 18 years+ - NCT03117036Recruiting
Study follows people with Hodgkin or non-Hodgkin lymphoma
This study enrolls adults with Hodgkin or non-Hodgkin lymphoma who plan to receive chemotherapy aimed at cure. It may help doctors better understand outcomes and how lymphoma care is managed over time.
SeoulAges 20–90 - NCT03681561RecruitingPhase 1/Phase 2
Nivolumab plus ruxolitinib for relapsed Hodgkin lymphoma
This trial tests nivolumab (an immune therapy) combined with ruxolitinib (a drug that targets immune signaling) for people whose classical Hodgkin lymphoma has come back or did not respond. It may help shrink the lymphoma and improve disease control after prior treatments, including checkpoint inhibitor therapy.
Chicago, IllinoisAges 18 years+ - NCT03852407RecruitingPhase 2
Two kinds of conditioning before matched stem cell transplant
This trial compares two reduced-intensity conditioning regimens before you receive stem cells from a donor who matches your HLA type. It aims to find which approach works better and is safer for certain blood cancers.
AntwerpAges 18–75 - NCT06580002RecruitingPhase 2
Can Riluzole Help with Chemo Brain? A Pilot Study
This study tests if a medicine called riluzole (currently used for ALS) can help with 'chemo brain' – memory and thinking problems after cancer treatment. It is for people who feel their mental sharpness has declined after breast cancer therapy, certain chemotherapies, or brain radiation.
Orange, CaliforniaAges 18 years+
Hear when a new Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Hodgkin Lymphoma trials by city
Studies with a site in or near these metro areas.
Hodgkin Lymphoma trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for hodgkin lymphoma?
- Yes. Clin2 currently lists 420 recruiting hodgkin lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hodgkin lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hodgkin lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.